Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 03, 2023

SELL
$65.71 - $74.53 $11,630 - $13,191
-177 Reduced 4.82%
3,492 $242,000
Q4 2022

Feb 07, 2023

SELL
$68.48 - $81.09 $9,244 - $10,947
-135 Reduced 3.55%
3,669 $263,000
Q3 2022

Nov 10, 2022

BUY
$0.13 - $76.84 $5 - $3,150
41 Added 1.09%
3,804 $270,000
Q2 2022

Jul 29, 2022

SELL
$72.62 - $79.98 $138,994 - $153,081
-1,914 Reduced 33.71%
3,763 $290,000
Q1 2022

May 02, 2022

BUY
$61.48 - $73.72 $9,836 - $11,795
160 Added 2.9%
5,677 $415,000
Q4 2021

Feb 07, 2022

BUY
$53.63 - $62.52 $15,338 - $17,880
286 Added 5.47%
5,517 $344,000
Q3 2021

Oct 22, 2021

SELL
$59.17 - $69.31 $109,642 - $128,431
-1,853 Reduced 26.16%
5,231 $310,000
Q2 2021

Jul 29, 2021

SELL
$61.91 - $67.42 $162,389 - $176,842
-2,623 Reduced 27.02%
7,084 $473,000
Q1 2021

May 10, 2021

SELL
$59.34 - $66.74 $79,396 - $89,298
-1,338 Reduced 12.11%
9,707 $613,000
Q3 2020

Nov 12, 2020

SELL
$57.43 - $63.64 $91,428 - $101,314
-1,592 Reduced 12.6%
11,045 $666,000
Q2 2020

Aug 13, 2020

SELL
$54.82 - $64.09 $5,262 - $6,152
-96 Reduced 0.75%
12,637 $743,000
Q1 2020

May 14, 2020

SELL
$46.4 - $67.43 $74,054 - $107,618
-1,596 Reduced 11.14%
12,733 $774,000
Q4 2019

Jan 27, 2020

SELL
$49.21 - $64.19 $33,856 - $44,162
-688 Reduced 4.58%
14,329 $920,000
Q3 2019

Dec 02, 2019

SELL
$42.77 - $50.71 $44,181 - $52,383
-1,033 Reduced 6.44%
15,017 $762,000
Q2 2019

Nov 27, 2019

SELL
$44.62 - $49.34 $47,921 - $52,991
-1,074 Reduced 6.27%
16,050 $728,000
Q1 2019

Nov 27, 2019

SELL
$45.12 - $53.8 $123,944 - $147,788
-2,747 Reduced 13.82%
17,124 $817,000
Q4 2018

Nov 27, 2019

BUY
$48.76 - $63.23 $968,909 - $1.26 Million
19,871 New
19,871 $1.03 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Beck Bode, LLC Portfolio

Follow Beck Bode, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Beck Bode, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Beck Bode, LLC with notifications on news.